<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590980</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0599</org_study_id>
    <secondary_id>5R01NS059745</secondary_id>
    <nct_id>NCT00590980</nct_id>
  </id_info>
  <brief_title>Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)</brief_title>
  <acronym>VERiTAS</acronym>
  <official_title>The Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sepideh Amin-Hanjani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with blockage of the blood vessels that supply blood to the back of the brain, known
      as vertebrobasilar disease (VBD), are at risk of having a stroke or temporary symptoms of a
      stroke known as transient ischemic attack (TIA). The risk of repeated stroke associated with
      VBD may be affected by several risk factors, including the degree to which the blockage
      reduces the blood flow to the brain. Patients with VBD have different levels of blockage
      ranging from partial blockage to complete blockage, which can affect the blood flow to the
      brain by variable amounts. The purpose of this research is to determine if patients with
      symptomatic VBD who demonstrate low blood flow to the back of the brain on magnetic resonance
      (MR)imaging are at higher risk of developing another stroke or TIA than patients with normal
      blood flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 700,000 strokes occur annually in the U.S. making it the third leading cause of
      death and the leading cause of permanent disability among adults. Over one third of strokes
      occur in the posterior circulation, the leading cause of which is vertebrobasilar occlusive
      disease secondary to atherosclerosis. Symptomatic vertebrobasilar disease (VBD) carries a
      high annual risk of stroke, averaging 10-15% per year despite medical therapy. This
      represents a potentially treatable high risk stroke etiology. Advances in endovascular
      angioplasty and stenting have created new treatment options, but these interventions carry
      significant risks, and the selection criteria for appropriate candidates remains uncertain.
      Determining predictors of stroke in this population is the first step toward identifying
      those high risk patients most suitable for consideration of intervention. Our preliminary
      studies suggest that the risk of stroke in VBD is strongly related to the extent to which
      intracranial blood flow is compromised.

      The objective is to conduct a longitudinal study of patients with symptomatic VBD. Our
      central hypothesis is that patients with symptomatic VBD who demonstrate limitation of blood
      flow on quantitative magnetic resonance angiography (QMRA) are at higher risk of stroke.The
      primary aim of this proposal is to test the hypothesis that among patients with VBD, those
      with distal blood flow compromise are at higher risk of subsequent posterior circulation
      stroke than those with normal flow.

      Secondary exploratory aims of the proposal are to determine:the correlation between large
      vessel flow measured by QMRA and tissue level perfusion measured by MR perfusion in the
      posterior circulation, and the predictive value of each; other predictive factors for stroke
      in this population; hemodynamic effects of varying degrees of vertebrobasilar stenosis;
      changes in hemodynamic status of patients on medical therapy over time; utility of QMRA as a
      non-invasive screening and monitoring tool in VBD.

      The study is a prospective multi-center observational cohort study of patients with
      symptomatic angiographically confirmed vertebrobasilar atherostenosis (≥ 50%), or occlusion).
      Upon enrollment, patients will undergo hemodynamic assessment with noninvasive MR imaging
      (including QMRA and MR perfusion), the results of which will be kept blinded from treating
      physicians and the patients. Patients will be prospectively designated as demonstrating
      compromised or normal distal cerebral flow based upon an existing validated algorithm of
      individual posterior circulation vessel flow measurements. Baseline demographic, clinical and
      laboratory data will be gathered. Subsequently, patients will have monthly clinical follow-up
      and be re-imaged with QMRA at 6 month intervals for a minimum of 12 months. The primary
      endpoint will be stroke incidence in the vertebrobasilar territory at one year. Survival
      analysis methods, with censoring of patients not achieving endpoint at the end of the study
      period, will be used for comparison of patients with compromised versus normal blood flow.

      The overall goal of the study is to define the population of patients with symptomatic VBD at
      highest risk of recurrent ischemic events. The information gained can significantly impact
      the selection criteria and likelihood for success of future clinical trials aimed at
      assessing the efficacy of endovascular or surgical interventions for the treatment of VBD.
      Moreover, the ability to define a low risk population in whom the risks of expensive invasive
      interventions would be unnecessary will have an equally important impact on the management of
      the disease both from a clinical and cost perspective. Data regarding the hemodynamic effects
      and changes over time of vertebrobasilar occlusive disease may also enhance our understanding
      of the basic pathophysiology and mechanisms of stroke in this morbid disease entity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory</measure>
    <time_frame>up to 27 months</time_frame>
    <description>Definite fatal and nonfatal ischemic stroke in the vertebrobasilar territory</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Vertebrobasilar Insufficiency</condition>
  <condition>Ischemic Attack, Transient</condition>
  <condition>Cerebrovascular Disorder</condition>
  <condition>Brain Ischemia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Neurology/Neurosurgery Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stroke or TIA in the vertebrobasilar territory

          -  Conventional or CT angiographic demonstration of ≥50% stenosis or occlusion of
             extracranial or intracranial vertebrobasilar artery

          -  Symptoms within 60 days of enrollment

          -  Age 18 and above

          -  Able to provide informed consent

        Exclusion Criteria:

        Neurologic criteria:

          -  Major disabling stroke prohibiting the ability to return for follow-up assessment

          -  Any neurological disease which would confound follow-up assessment

        Medical criteria:

          -  Any severe co-morbidity condition with less than 12 month life expectancy

          -  Known cardiac disease associated with cardioembolic risk specifically atrial
             fibrillation, prosthetic valves, endocarditis, left atrial/ventricular thrombus,
             cardiomyopathy with EF&lt;25%, cardiac myxoma

          -  Blood dyscrasias, specifically polycythemia vera, essential thrombocytosis, sickle
             cell disease

        Disease criteria:

          -  Non-atherosclerotic disease vertebrobasilar disease including dissection,
             fibromuscular dysplasia, vasculitis, radiation induced vasculopathy

          -  Unilateral vertebral stenosis or occlusion

        Patient criteria:

          -  Unable or unwilling to undergo MRI or cerebral angiography or CTA

          -  Pregnancy concurrent participation in an interventional trial for treatment of
             vertebrobasilar disease.

          -  Renal dysfunction will be exclusionary if it precludes angiography. No subjects will
             be excluded based upon gender, race, ethnic group, religion or socioeconomic status.
             Children will not be recruited as atherosclerotic VBD is a condition that affects
             adults primarily in later life and is not a disease that occurs or is relevant in
             children.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sepideh Amin-Hanjani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois, Department of Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles - UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Kramer, MDSC at Mercy Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN-Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://veritas.neur.uic.edu/</url>
    <description>VERiTAS Study website</description>
  </link>
  <reference>
    <citation>Amin-Hanjani S, Du X, Zhao M, Walsh K, Malisch TW, Charbel FT. Use of quantitative magnetic resonance angiography to stratify stroke risk in symptomatic vertebrobasilar disease. Stroke. 2005 Jun;36(6):1140-5. Epub 2005 May 12.</citation>
    <PMID>15890993</PMID>
  </reference>
  <reference>
    <citation>Amin-Hanjani S, Rose-Finnell L, Richardson D, Ruland S, Pandey D, Thulborn KR, Liebeskind DS, Zipfel GJ, Elkind MS, Kramer J, Silver FL, Kasner SE, Caplan LR, Derdeyn CP, Gorelick PB, Charbel FT; VERiTAS Study Group. Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS): rationale and design. Int J Stroke. 2010 Dec;5(6):499-505. doi: 10.1111/j.1747-4949.2010.00528.x.</citation>
    <PMID>21050408</PMID>
  </reference>
  <results_reference>
    <citation>Amin-Hanjani S, Du X, Rose-Finnell L, Pandey DK, Richardson D, Thulborn KR, Elkind MS, Zipfel GJ, Liebeskind DS, Silver FL, Kasner SE, Aletich VA, Caplan LR, Derdeyn CP, Gorelick PB, Charbel FT; VERiTAS Study Group. Hemodynamic Features of Symptomatic Vertebrobasilar Disease. Stroke. 2015 Jul;46(7):1850-6. doi: 10.1161/STROKEAHA.115.009215. Epub 2015 May 14.</citation>
    <PMID>25977279</PMID>
  </results_reference>
  <results_reference>
    <citation>Amin-Hanjani S, Pandey DK, Rose-Finnell L, Du X, Richardson D, Thulborn KR, Elkind MS, Zipfel GJ, Liebeskind DS, Silver FL, Kasner SE, Aletich VA, Caplan LR, Derdeyn CP, Gorelick PB, Charbel FT; Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke Study Group. Effect of Hemodynamics on Stroke Risk in Symptomatic Atherosclerotic Vertebrobasilar Occlusive Disease. JAMA Neurol. 2016 Feb;73(2):178-85. doi: 10.1001/jamaneurol.2015.3772.</citation>
    <PMID>26720181</PMID>
  </results_reference>
  <results_reference>
    <citation>Amin-Hanjani S, Turan TN, Du X, Pandey DK, Rose-Finnell L, Richardson D, Elkind MS, Zipfel GJ, Liebeskind DS, Silver FL, Kasner SE, Gorelick PB, Charbel FT, Derdeyn CP; VERiTAS Study Group. Higher Stroke Risk with Lower Blood Pressure in Hemodynamic Vertebrobasilar Disease: Analysis from the VERiTAS Study. J Stroke Cerebrovasc Dis. 2017 Feb;26(2):403-410. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.044. Epub 2016 Oct 28.</citation>
    <PMID>28029608</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>September 18, 2017</results_first_submitted>
  <results_first_submitted_qc>October 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2017</results_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sepideh Amin-Hanjani</investigator_full_name>
    <investigator_title>Professor, Department of Neurosurgery, University of Illinois at Chicago</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>TIA (transient ischemic attack)</keyword>
  <keyword>Brain</keyword>
  <keyword>Blood Flow</keyword>
  <keyword>Quantitative magnetic resonance angiography (QMRA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Vertebrobasilar Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet all inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population consists of all participants meeting all inclusion/exclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Study Participants</title>
          <description>Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" lower_limit="39" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory</title>
        <description>Definite fatal and nonfatal ischemic stroke in the vertebrobasilar territory</description>
        <time_frame>up to 27 months</time_frame>
        <population>Study participants meeting all inclusion and exclusion criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory</title>
          <description>Definite fatal and nonfatal ischemic stroke in the vertebrobasilar territory</description>
          <population>Study participants meeting all inclusion and exclusion criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year duration of participant participation.</time_frame>
      <desc>(AE) - related to the protocol MR imaging or angiogram (if the angiogram was performed as part of the study).
(SAE) - related to the protocol MR imaging or angiogram results in the usual definition of an SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Observation</title>
          <description>Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sepideh Amin-Hanjani, MD</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-996-4842</phone>
      <email>hanjani@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

